Last reviewed · How we verify
Experimental: Arm A: DRL_RI
This drug is a dopamine receptor D2/D3 antagonist.
This drug is a dopamine receptor D2/D3 antagonist. Used for Schizophrenia, Bipolar disorder.
At a glance
| Generic name | Experimental: Arm A: DRL_RI |
|---|---|
| Sponsor | Dr. Reddy's Laboratories Limited |
| Drug class | Dopamine antagonist |
| Target | D2/D3 receptor |
| Modality | Biologic |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
It works by blocking the action of dopamine at D2/D3 receptors in the brain, which may help reduce symptoms of schizophrenia and other psychiatric disorders.
Approved indications
- Schizophrenia
- Bipolar disorder
Common side effects
- Akathisia
- Dystonia
- Parkinsonism
- Somnolence
- Weight gain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental: Arm A: DRL_RI CI brief — competitive landscape report
- Experimental: Arm A: DRL_RI updates RSS · CI watch RSS
- Dr. Reddy's Laboratories Limited portfolio CI